[Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports].
Administration of intravesical chemotherapy by mitomycin C (MMC) is an adjuvant treatment of the recurrent superficial bladder cancer. Since use of MMC in 1967, many different toxicities were reported. Those are local toxicities. Systemic toxicity is rare. At the hand of 2 cases reports and recent literature, we discuss the possible complications of intravesical therapy with MMC.
Pouya
M
M
Service Urologie, Cliniques Universitaires Saint-Luc, Bruxelles.
Opsomer
R J
RJ
Wese
F X
FX
Saleh
M
M
Donnay
M
M
Van Cangh
P J
PJ
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D002114:Calcinosis / Q000139:chemically induced; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003556:Cystitis / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D009336:Necrosis / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins
Complications de la chimiothérapie intravésicale par la mitomycine, à propos de deux observations cliniques.